These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25183445)

  • 21. Replacement, reduction and refinement.
    Flecknell P
    ALTEX; 2002; 19(2):73-8. PubMed ID: 12098013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ["Replacement Methods to Animal Testing" as the incentive topic of the German Ministry of Education and Research. Selected results on biological drugs].
    Diekmann W; Hansper M
    ALTEX; 2001; 18(1):23-8. PubMed ID: 11248846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Microbiological and biological methods of the European Pharmacopoeia. Relevant for each medicinal product].
    Norwig J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1158-68. PubMed ID: 25200487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three Rs potential in the development and quality control of immunobiologicals.
    Halder M
    ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Replacement, reduction or refinement of animal use in the quality control of veterinary vaccines: development, validation and implementation.
    van der Kamp MD
    Dev Biol Stand; 1996; 86():73-6. PubMed ID: 8785994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Viral safety of biological medicinal products].
    Stühler A; Blümel J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1198-202. PubMed ID: 25123140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International reference preparations for standardization of biological medicinal products.
    Minor P
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1145-51. PubMed ID: 25204274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulatory acceptance and use of 3R models: a multilevel perspective.
    Schiffelers MJ; Blaauboer BJ; Hendriksen CF; Bakker WE
    ALTEX; 2012; 29(3):287-300. PubMed ID: 22847256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The current revision of Directive 86/609/EWG from the perspective of animal welfare legislation].
    Binder R; Lengauer E
    ALTEX; 2006; 23(3):179-85. PubMed ID: 17086347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concept of biosimilar products in Jordan.
    Haddadin RD
    Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FRAME - reflections on the future and challenges to success.
    Flower C
    Altern Lab Anim; 2009 Dec; 37 Suppl 2():53-5. PubMed ID: 20105013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Legal framework and legal-philosophical limitations in research].
    Schmidt-Jortzig E
    ALTEX; 2002; 19(4):192-4. PubMed ID: 12457204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Duties of the Central Office for Documentation and Evaluation of Alternative and Supplementary Methods for Animal Experimentation at the Institute for Veterinary Medicine of the Federal Health Office, Berlin].
    Grune-Wolff B
    Dtsch Tierarztl Wochenschr; 1993 Feb; 100(2):52-4. PubMed ID: 8462420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The development and approval of alternative methods to bioassays used for quality assurance, a challenge for the pharmaceutical industry and the authorities].
    Miethe G; Sponer G
    ALTEX; 2002; 19(3):115-21. PubMed ID: 12165813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the application of the 3Rs: a survey among animal welfare officers in The Netherlands.
    van Luijk J; Cuijpers Y; van der Vaart L; de Roo TC; Leenaars M; Ritskes-Hoitinga M
    Lab Anim; 2013 Jul; 47(3):210-9. PubMed ID: 23579322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implementation and enforcement of the 3Rs principle in the field of transgenic animals used for scientific purposes. Report and recommendations of the BfR expert workshop, May 18-20, 2009, Berlin, Germany.
    Kretlow A; Butzke D; Goetz ME; Grune B; Halder M; Henkler F; Liebsch M; Nobiling R; Oelgeschlaeger M; Reifenberg K; Schaefer B; Seiler A; Luch A
    ALTEX; 2010; 27(2):117-34. PubMed ID: 21445538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Test guideline development and animal welfare: regulatory acceptance of in vitro studies.
    Koëter HB
    Reprod Toxicol; 1993; 7 Suppl 1():117-23. PubMed ID: 8400630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of organizational culture in compliance with the principles of the 3Rs.
    Brønstad A; Berg AG
    Lab Anim (NY); 2011 Jan; 40(1):22-6. PubMed ID: 21173772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Replacement of in vivo acute oral toxicity studies by in vitro cytotoxicity methods: opportunities, limits and regulatory status.
    Ukelis U; Kramer PJ; Olejniczak K; Mueller SO
    Regul Toxicol Pharmacol; 2008 Jun; 51(1):108-18. PubMed ID: 18362045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developing alternatives to systemic toxicity testing approaches.
    von Aulock S
    ALTEX; 2012; 29(1):1. PubMed ID: 22408846
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.